New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
14:25 EDTQGEN, QGEN, NSPH, NSPH, ILMN, ILMN, HOLX, HOLX, BRKR, BRKR, BDX, BDX, ABT, ABT, TMO, TMOLeerink analyst/industry conference call on June 26 is now 2 pm
Life Science Tools & Diagnostics Analyst Leonard discusses trends and controversies in molecular diagnostics on an Analyst/Industry conference call. Relevant companies ABT, BDX, BRKR, HOLX, ILMN, NSPH, QGEN and TMO may be included on the Analyst/Industry conference call to be held on June 26 at 2 pm.
News For QGEN;NSPH;ILMN;HOLX;BRKR;BDX;ABT;TMO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
January 28, 2015
08:40 EDTILMNIllumina price target raised to $221 from $192 at Janney Capital
Subscribe for More Information
08:27 EDTILMNIllumina price target raised to $234 from $220 at BofA/Merrill
BofA/Merrill raised Buy rated Illumina's price target to $234 citing strong Q4 organic sales momentum.
08:13 EDTQGENQIAGEN management to meet with Evercore ISI
Subscribe for More Information
07:59 EDTILMNIllumina price target raised to $225 from $195 at Leerink
Subscribe for More Information
January 27, 2015
16:09 EDTILMNIllumina sees FY15 non-GAAP EPS $3.12-$3.18, consensus $3.20
For FY15 the Company is projecting approximately 20% revenue growth, assuming current currency exchange rates, and non-GAAP EPS of $3.12-$3.18. These projections assume full year non-GAAP gross margin of approximately 73%, and a pro forma tax rate of approximately 28%.
16:08 EDTILMNIllumina reports Q4 non-GAAP EPS 87c, consensus 78c
Reports Q4 revenue $512M, consensus $507.65M.
16:06 EDTQGENQIAGEN launches monitor to track immune function in organ transplant patients
QIAGEN N.V. announced the commercial launch of QuantiFERON Monitor, a diagnostic for monitoring immune function. QIAGEN is launching QuantiFERON Monitor in Europe as a CE-marked in-vitro diagnostic. Primary applications include monitoring of immune function in solid organ transplant recipients. In North America and other markets, QFM is available for research use as an accurate marker of immune function in studies of immunosuppressive conditions, immune modulating therapies and recovery following transplantation.
15:04 EDTQGENQIAGEN management to meet with Leerink
Meeting to be held in New York on February 3 hosted by Leerink.
12:51 EDTHOLXHologic February volatility elevated into Q1 and outlook
Hologic February call option implied volatility is at 36, March is at 31, June is at 29; compared to its 26-week average of 31 according to Track Data, suggesting larger price movement into the expected release of Q1 results in January 28.
January 23, 2015
15:46 EDTHOLX, ILMNPiper Jaffray's medtech analysts hold an analyst/industry conference call
Subscribe for More Information
January 21, 2015
16:48 EDTBDXCareFusion stockholders approve proposed merger with Becton, Dickinson
Becton, Dickinson and Company (BDX) and CareFusion (CFN) announced the results of the CareFusion special meeting of stockholders, held on January 21, for CareFusion stockholders to consider and vote upon the proposed merger of CareFusion and BD. CareFusion stockholders approved the definitive merger agreement and the merger transaction, with approximately 76% of shares outstanding cast in favor of the proposal. As previously announced on October 5, 2014, BD and CareFusion entered into a definitive agreement pursuant to which BD would acquire CareFusion in a stock and cash transaction. CareFusion stockholder approval was a condition to the merger. The proposed acquisition remains subject to certain other conditions and approvals, including approval of the proposed acquisition by the European Commission under the European Union Merger Regulation.
10:24 EDTILMNIllumina pulls back following State of the Union address
Shares of Illumina (ILMN) rose yesterday after a biotech industry website reported that President Obama might unveil a major new genomics project during his State of the Union address last night. That speculation was backed as a possibility by an analyst at Wells Fargo ahead of last night's address. In the speech, President Obama unveiled what he called his Precision Medicine Initiative, which relies on genomics to "deliver(s) the right treatment at the right time." Obama spent far more time, however, discussing economic growth and foreign relations than healthcare. Illumina shares are down 3% to $190.64 in early trading today.
10:01 EDTBDXOn the Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Ashford Hospitality (AHT) upgraded to Outperform from Neutral at Credit Suisse... BAE Systems (BAESY) upgraded to Buy from Neutral at Goldman... Bazaarvoice (BV) upgraded to Outperform from Market Perform at Cowen... Becton Dickinson (BDX) upgraded to Outperform at Cowen... CVS Health (CVS) upgraded to Buy from Neutral at Goldman... Camden Property (CPT) upgraded to Outperform from Neutral at Credit Suisse... ConocoPhillips (COP) upgraded to Buy from Neutral at BofA/Merrill... Cornerstone OnDemand (CSOD) upgraded to Buy from Neutral at DA Davidson... Cree (CREE) upgraded to Overweight at Stephens... DDR Corp. (DDR) upgraded to Outperform from Neutral at Credit Suisse... EastGroup Properties (EGP) upgraded to Outperform from Neutral at Credit Suisse... Energy Transfer Partners (ETP) upgraded to Outperform from Neutral at Credit Suisse... Esperion (ESPR) upgraded at BofA/Merrill... Exxon Mobil (XOM) upgraded to Outperform from Market Perform at Wells Fargo... FXCM (FXCM) upgraded to Market Perform from Underperform at Keefe Bruyette... Fair Isaac (FICO) upgraded to Overweight from Equal Weight at Barclays... Golar LNG (GLNG) upgraded to Buy from Hold at Nordea... Gran Tierra (GTE) upgraded to Buy at Canaccord... Host Hotels (HST) upgraded to Outperform from Neutral at Credit Suisse... J.M. Smucker (SJM) upgraded to Overweight from Neutral at JPMorgan... Kilroy Realty (KRC) upgraded to Neutral from Underperform at Credit Suisse... Level 3 (LVLT) upgraded to Outperform from Market Perform at Wells Fargo... Lowe's (LOW) upgraded to Overweight from Equal Weight at Morgan Stanley... Michael Kors (KORS) upgraded to Outperform at Cowen... Netflix (NFLX) upgraded at Nomura... Regions Financial (RF) upgraded to Buy from Neutral at Guggenheim... Ruckus Wireless (RKUS) upgraded to Outperform from Market Perform at Northland... Santander Mexico (BSMX) upgraded to Neutral from Underperform at Credit Suisse... Scorpio Tankers (STNG) upgraded to Buy at Canaccord... Sprouts Farmers Markets (SFM) upgraded to Buy from Neutral at BofA/Merrill... Strategic Hotels (BEE) upgraded to Outperform from Neutral at Credit Suisse... The Medicines Co. (MDCO) upgraded to Outperform from Market Perform at Leerink... Whole Foods (WFM) upgraded at Sterne Agee... Wolseley (WOSYY) upgraded to Neutral from Underperform at Exane BNP Paribas.
09:23 EDTBDXRetractable Tech says judge issues final judgment in suit against Becton Dickinson
Subscribe for More Information
08:00 EDTBDXBecton Dickinson upgraded to Outperform at Cowen
As previously reported, Cowen upgraded Becton Dickinson (BDX) to Outperform from Market Perform as they believe synergy targets for its Carefusion (CFN) acquisition are too low. Cowen raised its price target to $165 form $130 on Becton Dickinson shares.
06:55 EDTBDXBecton Dickinson upgraded to Outperform from Market Perform at Cowen
Subscribe for More Information
January 20, 2015
13:45 EDTILMNIllumina rises as genomics project seen being announced in State of the Union
Subscribe for More Information
11:24 EDTILMNIllumina could see headline boost from U.S. genomics project, says Wells Fargo
After biotech industry publication BioCentury said Friday that the president may announce a new genomics project to sequence up to one million human genomes as part of his State of the Union speech tonight, Wells Fargo said that it believes such an announcement could be a headline catalyst for Illumina since it would mean the U.S. needs additional sequencing capacity. However, such a project would be long-term in nature, Wells Fargo cautioned, adding that such a plan would more likely support existing Illumina growth assumptions than push those forecasts up. Shares of Illumina are up 6% to $194.85 in morning trading ahead of tonight's speech by the president.
08:53 EDTHOLXHologic upgraded to Outperform from Market Perform at William Blair
Subscribe for More Information
08:30 EDTHOLXHologic upgraded to Outperform from Market Perform at William Blair
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use